Observational Registry of the Treatment of Glanzmann's Thrombasthenia
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This observational registry is conducted in Europe, Asia, Africa and the United States of
America (USA).
The purpose of the registry is to evaluate the efficacy and safety of activated recombinant
human factor VII (rFVIIa) during bleeding episodes and for the prevention of bleeding during
invasive procedures/surgery in patients with Glanzmann's thrombasthenia (GT) with past or
present refractoriness to platelet transfusions. Attention will be directed towards
complications related to thrombo-embolic events and concomitant medications especially
antifibrinolytics.